
Opinion|Videos|September 29, 2023
Safety Outcomes with Leuprolide
Author(s)Paul Sieber, MD
In the second interview of the series, Paul Sieber, MD, provides expert insights on the management of adverse effects seen in patients receiving leuprolide for the treatment of advanced/metastatic prostate cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Unmet needs and emerging solutions in MRI-guided prostate cancer care
2
HHS requests testosterone therapy label updates, citing new safety data
3
Microbial dysbiosis may predict response to CBM588 in mRCC
4
Eugene Pietzak, MD, on pembrolizumab plus BCG for BCG-naïve “very high risk” T1 NMIBC
5















